179 related articles for article (PubMed ID: 29507304)
61. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema.
Do DV; Nguyen QD; Shah SM; Browning DJ; Haller JA; Chu K; Yang K; Cedarbaum JM; Vitti RL; Ingerman A; Campochiaro PA
Br J Ophthalmol; 2009 Feb; 93(2):144-9. PubMed ID: 19174400
[TBL] [Abstract][Full Text] [Related]
62. Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab.
Bakri SJ; Donaldson MJ; Link TP
Eye (Lond); 2006 Dec; 20(12):1474-5. PubMed ID: 16680105
[No Abstract] [Full Text] [Related]
63. Panretinal Photocoagulation Plus Intravitreal Bevacizumab Versus Panretinal Photocoagulation Alone for Proliferative Diabetic Retinopathy.
Ali W; Abbasi KZ; Raza A
J Coll Physicians Surg Pak; 2018 Dec; 28(12):923-927. PubMed ID: 30501828
[TBL] [Abstract][Full Text] [Related]
64. Optic atrophy after anti-vascular endothelial growth factor injection in diabetic patients with proliferative diabetic retinopathy.
Singalavanija A; Hemarat K; Kedkovid N; Tanterdtham J; Namatra C; Trinavarat A; Rodanant N; Thoongsuwan S
J Med Assoc Thai; 2013 Mar; 96(3):318-23. PubMed ID: 23539935
[TBL] [Abstract][Full Text] [Related]
65. Aqueous Levels of Angiopoietin-like 4 and Semaphorin 3E Correlate with Nonperfusion Area and Macular Volume in Diabetic Retinopathy.
Kwon SH; Shin JP; Kim IT; Park DH
Ophthalmology; 2015 May; 122(5):968-75. PubMed ID: 25687026
[TBL] [Abstract][Full Text] [Related]
66. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
[TBL] [Abstract][Full Text] [Related]
67. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.
Spaide RF; Fisher YL
Retina; 2006 Mar; 26(3):275-8. PubMed ID: 16508426
[TBL] [Abstract][Full Text] [Related]
68. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema.
Mirshahi A; Shenazandi H; Lashay A; Faghihi H; Alimahmoudi A; Dianat S
Retina; 2010 Feb; 30(2):254-9. PubMed ID: 20057344
[TBL] [Abstract][Full Text] [Related]
69. Intravitreal ranibizumab or conbercept for retinal arterial macroaneurysm: a case series.
Lin Z; Hu Q; Wu Y; Xu J; Zhang Q
BMC Ophthalmol; 2019 Jan; 19(1):18. PubMed ID: 30646868
[TBL] [Abstract][Full Text] [Related]
70. [Clinical observation of a new anti-VEGF drugs conbercept for wet age-related macular degeneration].
Lu H; Cui J; Dong H; Luo B; Xiu W; Li H
Zhonghua Yan Ke Za Zhi; 2015 Nov; 51(11):818-21. PubMed ID: 26850582
[TBL] [Abstract][Full Text] [Related]
71. Vascular shunt of the optic disc resembling neovascularization in a diabetic patient with optic disc drusen.
Karagiannis DA; Sampat V; Gregor Z
Eur J Ophthalmol; 2006; 16(5):764-6. PubMed ID: 17061234
[TBL] [Abstract][Full Text] [Related]
72. Succinate increases in the vitreous fluid of patients with active proliferative diabetic retinopathy.
Matsumoto M; Suzuma K; Maki T; Kinoshita H; Tsuiki E; Fujikawa A; Kitaoka T
Am J Ophthalmol; 2012 May; 153(5):896-902.e1. PubMed ID: 22265145
[TBL] [Abstract][Full Text] [Related]
73. Influence of preoperative intravitreal bevacizumab on visual function in eyes with proliferative diabetic retinopathy.
Ushida H; Kachi S; Asami T; Ishikawa K; Kondo M; Terasaki H
Ophthalmic Res; 2013; 49(1):30-6. PubMed ID: 23038607
[TBL] [Abstract][Full Text] [Related]
74. Vitreous Fibronectin and Fibrinogen Expression Increased in Eyes With Proliferative Diabetic Retinopathy After Intravitreal Anti-VEGF Therapy.
Wei Q; Zhang T; Jiang R; Chang Q; Zhang Y; Huang X; Gao X; Jin H; Xu G
Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5783-5791. PubMed ID: 29117316
[TBL] [Abstract][Full Text] [Related]
75. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Jampol LM; Melia M; Peters MA; Rauser ME;
Ophthalmology; 2017 Apr; 124(4):431-439. PubMed ID: 28161147
[TBL] [Abstract][Full Text] [Related]
76. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
; Gross JG; Glassman AR; Jampol LM; Inusah S; Aiello LP; Antoszyk AN; Baker CW; Berger BB; Bressler NM; Browning D; Elman MJ; Ferris FL; Friedman SM; Marcus DM; Melia M; Stockdale CR; Sun JK; Beck RW
JAMA; 2015 Nov; 314(20):2137-2146. PubMed ID: 26565927
[TBL] [Abstract][Full Text] [Related]
77. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy.
González VH; Giuliari GP; Banda RM; Guel DA
Br J Ophthalmol; 2009 Nov; 93(11):1474-8. PubMed ID: 19692371
[TBL] [Abstract][Full Text] [Related]
78. Tractional retinal detachment after branch retinal vein occlusion. Influence of disc neovascularization on the outcome of vitreous surgery.
Ikuno Y; Ikeda T; Sato Y; Tano Y
Ophthalmology; 1998 Mar; 105(3):417-23. PubMed ID: 9499770
[TBL] [Abstract][Full Text] [Related]
79. New Findings in Diabetic Maculopathy and Proliferative Disease by Swept-Source Optical Coherence Tomography Angiography.
Stanga PE; Papayannis A; Tsamis E; Stringa F; Cole T; D'Souza Y; Jalil A
Dev Ophthalmol; 2016; 56():113-21. PubMed ID: 27023703
[TBL] [Abstract][Full Text] [Related]
80. INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA: A Pilot Study.
Andrade GC; Dias JR; Maia A; Farah ME; Meyer CH; Rodrigues EB
Retina; 2016 Sep; 36(9):1640-5. PubMed ID: 26991646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
